Phase 2, open-label, single arm, multicenter study of Encorafenib, Binimetinib plus Cetuximab in subjects with previously untreated BRAFV600E -mutant metastatic colorectal cancer

A randomized, single-center, open-label, single dose, two-period, crossover pivotal bioequivalence study comparing binimetinib 3 x 15 mg and 45 mg tablets in healthy participants

Adjuvant encorafenib & binimetinib vs. placebo in resected stage II BRAF V600E/K mutated melanoma: a randomized triple-blind Phase III Study in collaboration with the EORTC Melanoma Group.

A prospective, open-label, genotype-match controlled, multicenter clinical trial to investigate the efficacy and safety of intra-amniotic ER004 as a prenatal treatment for male subjects with X-linked hypohidrotic ectodermal dysplasia (XLHED)

An open label, multicentre, phase I study to evaluate the impact of moderate and severe hepatic impairments on the pharmacokinetics and safety of encorafenib in combination with binimetinib in adult patients with unresectable or metastatic BRAF V600-mutant solid tumors.

A multicenter, randomized, open-label, 2-arm, Phase II trial with a safety lead-in phase evaluating the combination of encorafenib and cetuximab versus irinotecan/cetuximab or infusional 5-fluorouracil (5-FU)/folinic acid (FA)/irinotecan (FOLFIRI)/cetuximab in Chinese patients with BRAFV600E mutant metastatic colorectal cancer.

Retrospective observational study of adult patients with early-stage HER-2 positive breast cancer, treated with neratinib as extended adjuvant therapy in the context of the European Early Access Program.

Multicentre, multi-country, prospective, observational, post-authorisation safety study to describe the incidence of discontinuation due to diarrhoea within the first 3 months of treatment with neratinib, in adult breast cancer patients treated in extended adjuvant in a real-world setting: the NERLYFE study..

A multicenter, open-label, phase 1 study investigating the safety and tolerability of encorafenib monotherapy in BRAF^V600E-mutated Chinese patients with advanced metastatic solid tumors

Multicenter, Open-label, Phase II Study with a Safety Lead-in part Investigating the Efficacy, Safety and Pharmacokinetics of Encorafenib and Binimetinib Combination in BRAF^V600E mutated Chinese Patients with Metastatic Non-Small Cell Lung Cancer who are BRAF- and MEK inhibitor treatment-naïve

An observational study describing diagnosis and treatment patterns in adults with metastatic non-small cell lung cancer with BRAF V600E mutation in clinical practice, to assess treatment effectiveness and quality of life.

A 6-months prospective, observational study to evaluate the quality of life of patients treated with phytotherapy or alpha-blockers for benign prostatic hyperplasia.

Study of the combination of Binimetinib and Encorafenib in adolescent patients with unresectable or Metastatic BRAF V600-mutant Melanoma

Non inferiority study of Metronidazole 0.75% cream versus reference therapy in the local treatment of papulopustular rosacea

Post-operative care by chlorhexidine mouthwash after periodontal surgery. Randomised, parallel groups; blind study, DC071BB versus placebo, in patients presenting with periodontal surgery with suture

Efficacy of DC071 mouthwash (0.2% chlorhexidine digluconate) in peri-surgical care for preventing alveolar osteitis after third molar extraction

Efficacy study of Ciclopiroxolamine 1% foam (DC115 GM 02A) versus Ciclopiroxolamine 1.5% shampoo (SEBIPROX®) in the treatment of moderate seborrheic dermatitis of the scalp

Assessment of the efficacy of a new formulation of minoxidil (DC120) on hair growth, in a minizone model in androgenetic alopecia in men.

Evaluation of the effect of 6 months treatment with DC158AM on fatigue in patients with Parkinson's disease. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups

Pharmacodynamic and clinical assessment of DC 982 GE (2,4 or 6 capsules per day) in patients with chronic venous disorders : randomised, placebo-controlled, dose effect, double blind, parallel group

Clinical and biophysics evaluation of the cutaneous modifications following the local use of a lotion containing 0,1 % of trétinoïne

The effect of Minalcipran 100mg BID on sensitivity to stimulus-evoked pain in patients with Fibromyalgia : a FMRI neuroimaging study

A European Phase III, multicentre, double-blind, randomised, placebo-controlled monotherapy study of Milnacipran for the treatment of the Fibromyalgia Syndrome

Exploratory study of the efficacy and safety of flexible doses of Milnacipran and Venlafaxine administered in out patients with Major Depressive Disorder

A european Phase III, multicentre, double-blind, randomised, monotherapy, 12-month study of Minalcipran for the treatment of the Fibromyalgia Syndrome

A double blind, multinational, multicentre, placebo controlled 10-week study assessing the efficacy and safety of F2695 SR flexible dose (75, 100 mg/day) in the treatment of patients with major depression

Effect of 3-month treatment with F2695 (75mg OD) on improving functional recovery of patients with ischemic stroke. A multicenter, randomised, double-blind, parallel-group, placebo-controlled study

A dose-finding study of efficacy and safety of F13640 in patients with moderate to severe painful peripheral diabetic polyneuropathy

Proof of Concept study of the efficacy and tolerability of a 4-week treatment with F13640 in patients in whom the adaptation of opioid therapy of cancer pain has failed. A prospective, multinational, multicentre, randomised, double-blind, placebo-controlled study.

Study of the analgesic effects of repeated doses of F13640 in spinal cord injury patients with moderate to severe central neuropathic pain. A multinational, multicenter, randomized, double blind, parallel groups, placebo-controlled study.

Phase I-II study of F14512 in combination with cytarabine in patients 60 years old and older with acute myeloid leukemia

Effects of F17464 in acute exacerbation of schizophrenia

Phase I-II study of F17752 in patients with advanced solid tumors

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure

A phase II multicentric study in adults with acute myelogenous leukaemia (AML) in first complete remission (CR1) using IV BuCy2 in a once daily Bu regimen targeting a narrow therapeutic window prior t...

Exploratory study of besipirdine efficacy and safety in male patients with persistent stress urinary incontinence after radical prostatectomy

Clinical efficacy and safety of J022X ST in the prevention of Recurrent Upper-Respiratory Tract Infections (RURTI) in children with a high risk of recurrence

Clinical trial of the efficacy and tolerability of an immunostimulant drug, composed by ribosomal fractions, in socialized paediatric patients in order to prevent recurrent respiratory infections

Comparative study of the effect of 4-week treatment with ossein-hydroxyapatite compound versus calcium carbonate on bone biomarkers in young women with low calcium intake. Prospective, monocenter, randomized, open-label, two-period,cross-over trial

Effect of treatment with ossein-hydroxyapatite compound on the time of fracture-healing". A prospective, multicenter, double-blind, randomised, placebo controlled clinical trial

Treat study : treatment of iron deficiency anaemia with Tardyferon. Importance of prolonging iron supplementation in anemic women of childbearing age

Efficacy of an early administration of L0013CP 10 MG/DAY versus placebo during 4 weeks in the treatment of infectious diseases induced arthritis painful symptoms. A multicenter, randomised, double-blind, placebo controlled clinical trial in adult patients suffering from Chikungunya fever

Etude randomisée, en groupes parallèles, en double insu, de l'efficacité de la méquitazine sur la symptomatologie et l'obstruction nasale chez des patients présentant une rhinite allergique perannuelle

Effects of TANGANIL (three 500 mg tablets twice daily) on postural disturbances in the elderly

Efficacy and tolerability of Chondroitin Sulphate 1000mg, twice daily in patients with symptomatic knee osteoarthritis

Efficacy and safety assessment of 6 months (24 weeks) treatment with Structum® 500 mg capsule bid in hip osteoarthritis: multicenter randomised double blind parallel group and placebo controlled study

Comparative study of efficacy and safety of Structum® and Chondrosulf® in patients with symptomatic osteoarthritis of the knee.A Multicenter, Randomized, Double-Blind, Double Placebo-Controlled, Parallel Group Study

Randomized phase II study assessing the combination of Vinflunine with Gemcitabine and Vinflunine with Carboplatin in patients ineligible to cisplatin with advanced or metastatic transitional cell carcinoma of the urothelium

Phase II study assessing the maintenance treatment with vinflunine after first-line therapy with gemcitabine and cisplatin in patients with advanced or metastatic transitional cell carcinoma of the urothelial tract

Phase III study of vinflunine plus gemcitabine versus paclitaxel plus gemcitabine in patients with unresectable, locally recurrent or metastatic breast cancer after prior anthracycline-based adjuvant chemotherapy

A phase III trial of vinflunine + capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with or resistant to an anthracycline and who are taxane resistant

Phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite, and a vinca-alkaloid (study L00070 IN 308 B0)

Phase III study of IV vinflunine in combination with methotrexate versus methotrexate alone in patients with recurrent or metastatic squamous cell carcinoma of the head and neck previously treated with platinum-based chemotherapy (study L00070 IN 309 F0)

Phase III study of Vinflunine plus Capecitabine versus Capecitabine alone in patients with advanced breast cancer

Randomized phase III study comparing vinflunine-gemcitabine and gemcitabine-carboplatin combinations in patients ineligible to cisplatin with advanced or metastatic urothelial carcinoma

Cross over comparison of Testosterone serum levels in Hypogonadal men treated with L0074 Testosterone Patch 60 cm2 (2 patches/48H) and oral Testosterone Undecaoate -PANTESTONE® 40mg- (2 caps, bid)

Transdermal testosterone supplementation in elderly hypogonadal men with sarcopenia: effects on muscle function, physical performance, body composition and quality of life." A randomized, double-blind, placebo-control, parallel-group study on 150 patients

Evaluation of erectyle disfonction in patients suffering from testosterone deficiency, before and after tretament by Testopatch

Etude en double aveugle versus placebo de l'efficacité et de la tolérance de Cirkan® sur la symptomatologie fonctionnelle veineuse éprouvée (C0s à C3s) par les patientes obèses

A retrospective non interventional study on first line treatment for patientswWith BRAF V600E mutant metastatic colorectal cancer (mCRC) (CAPSTAN CRC)

Ensayo clínico en fase I-II de vinorelbina oral (Navelbine) en combinación con capecitabina en tratamiento de primera línea en pacientes con cáncer de mama avanzado

Exploratory study of L.S.E.S.r. (PERMIXON® 160 mg hard capsule) versus Tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH, A multinational, multicen...

PERMIXON® 160 mg hard capsule versus placebo in the treatment n the treatment of symptomatic lower urinary tract symptoms due to benign prostatic hyperplasia

Randomised phase II trial of oral vinorelbine and cisplatin followed by maintenance with single agent oral vinorelbine versus gemcitabine and cisplatin followed by maintenance with single agent gemcitabine in first line Locally Advanced or Metastatic Non-Small-Cell Lung Cancer patients with squamous histological type

Randomized Phase II study comparing single agent oral vinorelbine administered with two different schedules in patients with Advanced Non Small Cell Lung Cancer unfit for a platinum-based chemotherapy

Randomised Phase II Study comparing, as first-line chemotherapy, single-agent Oral Vinorelbine administered with two different schedules in patients with Advanced Breast Cancer

Phase II trial of oral vinorelbine in combination with capecitabine and trastuzumab as first line therapy in women with previously untreated HER2 positive metastatic breast cancer

Phase II Study of Navelbine oral and Arimidex as neo-adjuvant treatment in post-menopausal women with locally advanced breast carcinoma

Phase II trial of oral vinorelbine in combination with capecitabine as first line therapy in women with previously untreated HER2 negative metastatic breast cancer

Phase II study of oral vinorelbine in combination with capecitabine in metastatic breast cancer patients previously treated with anthracyclines and taxanes

A Randomised Phase II study of Oral Vinorelbine or I.V. Vinorelbine in patients with metastatic breast cancer previously treated with anthracyclines

Randomised phase II study of the combination of oral vinorelbine with capecitabine versus a sequential regimen of oral vinorelbine and capecitabine versus the combination of docetaxel and capecitabine...

Randomised phase II study of the combination of oral vinorelbine with capecitabine versus gemcitabine in combination with paclitaxel versus gemcitabine in combination with docetaxelchemotherapy in patients with metastatic breast cancer.

Evaluation Of The Rate Of Pathological Complete Response (pCR) For Neoadjuvant Chemoradiotherapy (CT-RT) And For Chemotherapy (CT) Alone in Locally Advanced Non Small Cell Lung Cancer (LA-NSCLC): A Randomized Phase II trial

Prospective randomised phase II trial of oral vinorelbine and cisplatin or pemetrexed and cisplatin in first line Metastatic or Locally Advanced Non-Small-Cell Lung Cancer patients with non-squamous histological type

Phase II study evaluating oral vinorelbine as a single agent in patients with hormone receptor breast cancer with bone metastases previously treated by a hormone therapy

Phase II trial of oral vinorelbine in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) positive mutation after failure or resistance to treatment with Tyrosine Kinase Inhibitors (TKI) in first line

Randomised phase II study evaluating, as first-line chemotherapy, weekly oral vinorelbine as a single-agent versus weekly paclitaxel as a single-agent in estrogen receptor positive, HER2 negative patients with advanced breast cancer

Prospective randomised clinical phase III trial of (alternating IV and oral) vinorelbine plus cisplatin versus docetaxel plus cisplatin in first line chemotherapy of locally advanced or metastatic non...

Oral Vinorelbine and Cisplatin with concomitant radiotherapy followed by either consolidation therapy with oral Vinorelbine and Cispalatine plus best supportive care or best supportive care alone in stage III Non Small Cell Lung Cancer (NSCLC): randomized Phase III study

Efficacy and safety of 0,1%, 0,5% and 1% TAZAROTENE nail lacquer formulation versus vehicle in nail psoriasis. International, multicenter, double-blind, randomized study of four parallel groups

A multicentre, randomized, controlled study of the efficacy, safety and cost-effectiveness of a sequential therapy with RV4104A ointment, ciclopiroxolamine cream and ciclopirox film-forming solution compared with amorolfine nail lacquer alone for the treatment of dermatophytic onychomycosis (toenail) without matrix involvement

An intra-individual randomised controlled study to evaluate the efficacy and tolerance of the product RV4421 A BS0042 in association with a moderately potent topical corticosteroid in adults with atopic dermatitis

Randomised, placebo-controlled, double-blind efficacy study of the emollient V0034CR in addition to a moderately potent corticosteroid in the acute phase of treatment of atopic dermatitis in infants

Long term management of atopic dermatitis with the emollient V0034CR. A randomised, placebo-controlled, parallel groups, double-blind study in infants and children

Long-term Efficacy and Safety of V0034 CR 01B Cream in Patients With Moderate-to-severe Uremic Xerosis

Efficacy and tolerance of the emollient cream V0034 CR in the symptomatic treatment of ichthyosis in children. International, multicentric, randomised, controlled, double blind study, in parallel group

Efficacy of the V0034CR01B emollient on xerosis in children with atopic dermatitis. Randomised, vehicle-controlled, parallel-groups, double-blind study with an open label extension

Emollients in the management of atopic dermatitis in children: prevention of flares

Effects of OMACOR in patients with a cardiac sodium channel gene SCN5A mutation, one variant of the congenital long-QT syndrome. A proof of concept study

Assessment of the activity of a new cream containing betamethasone dipropionate at 0.010%, 0.025% and 0.050% versus reference products using a vasoconstriction assay in healthy subjects

Efficacy and tolerance of V0071 GM 01A in inflammatory seborrhoeic dermatitis of the scalp.

Efficacy and safety of 8% Clobetasol nail lacquer formulation versus vehicle in nail psoriasis

Evaluation du pouvoir bactériostatique de la préparation V0079CR CETAVLON sur la flore cutanée au niveau des mains. Etude preuve de concept.

Efficacy of the topic RV3131A-HC3221 in the prevention of polymorphic light eruption

Reduction of the gingival inflammation by V0109 DI. Randomised, parallel groups, double blind study, V0109 DI versus placebo, in patients presenting gingivitis

Randomised, double-blind, placebo-controlled dose-effect study of V0114 (2.5, 5, 7.5 and 10 mg) versus mequitazine 10 mg and placebo in the treatment of seasonal allergic rhinitis

Efficacy and safety study of the antihistamine V0114CP 2.5MG tablet in the treatment of seasonal allergic rhinitis. A randomised, double blind, placebo controlled study

Efficacy and safety study of the antihistamine V0114CP 2.5MG in the treatment of perennial allergic rhinitis. Randomised, double blind, tree arm parallel group study including placebo and active control

EFFICACY AND SAFETY STUDY OF THE ANTIHISTAMINE V0114CP 2.5MG IN THE TREATMENT OF SEASONAL ALLERGIC RHINITIS. RANDOMISED, DOUBLE-BLIND, THREE ARM PARALLEL GROUP STUDY INCLUDING PLACEBO AND ACTIVE CONTROL ARM (DESLORATADINE 5 MG)

Efficacy and safety study of the antihistamine V00114CP 2.5 mg in the treatment of seasonal allergic rhinitis. Randomised, double-blind, three arm parellel group study including placebo and active control

Analysis of the sensory profile of two new transdermal patches (V0116TD07AF019 and V0116TD07AF020) 21 mg/24h versus a reference transdermal patch (NICOTINELL TTS) 21 mg/24h

Etude de l'efficacité de CIRKALM crème versus placebo dans le traitement des douleurs anales

A Phase II double-blind vehicle controlled crossover single dose (400 µG) V0147 gel effect and tolerance study in spinal cord injured patients with erectile dysfunction

Urodynamic effect of one single vaginal application of 2 mL of V0162 gel (0.8%) in post-menopausal women with overactive bladder

Bronchodilator properties and safety of a repeated dose of V0162 inhalation powder in asthma

Evaluation of the effect of 6 months treatment with V0191 on symptoms changes in patients with Mild Cognitive Impairment. Multicentre, randomised, double-blind, placebo-controlled study in parallel groups

A double-blind placebo controlled study of 1g, 2g and 4g V0251 efficacy and tolerance in vestibular neuritis

Effect of V0251 in acute vertigo. A randomized double blind placebo conrolled study

V0251 oral suspension efficacy and tolerance in vestibular neuritis. A randomised double-blind placebo controlled study

Study of efficacy and safety of V0305 solution in children suffering from Iron Deficiency Anaemia (IDA). Phase 3, multicentre, single arm open-label study

A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides

Impact of the V0034CR 01B emollient on atopic dermatitis symptoms in children. A randomised, placebo-controlled, parallel-groups, double-blind study

Efficacy and tolerability of 12-weeks oral treatment with V0355CP3A versus Ferrograd, in iron deficiency anaemia. Multicenter, randomised, open-label trial

Non inferiority study of a malathion 0.5% lotion versus reference therapy in the treatment of head lice: multicentre, randomised, investigator masked, parallel group

A randomised, double blind, controlled, multicentre study in infants with infantile hemangioma to compare propranolol gel to placebo

A multicentre, open-label, repeated-dose, pharmacokinetic study of Propranolol in infants treated for proliferating infantile hemangiomas (IHs) requiring systemic therapy

A randomised, controlled, multidose, multicentre, adaptive phase II/III study in infants with proliferating infantile hemangiomas requiring systemic therapy to compare four regimens of propranolol (1 or 3 mg/kg/day for 3 or 6 months) to placebo (double blind).

Efficacy and safety of Hemangiol solution in the treatment of high risk infantile hemangioma. A Multinational single arm study

Analgesic profile of 3 new Ibuprofen lozenges (V0498TA01A 15mg, 25mg,

Study of efficacy and safety of V0498 versus placebo in acute sore throat pain

A Randomized, single-center, open-label, single dose, two-period, crossover study to investigate the relative bioavailability of Binimetinib 3 x15 mg and 45 mg tablets in healthy participants

A prospective non interventional study on targeted therapy for patients with unresectable or metastatic BRAFV600E mutant melanoma (TAVIE-Skin)

Frequency and Intensity of local reactions in patients treated with 4% 5-FU vs 4% 5-FU associated with an emollient cream: a randomised, controlled clinical trial

Phase I/II open label dose escalation and dose expansion study of intravenous infusion of W0101, an antibody-drug conjugate, in patients with advanced or metastatic solid tumors. International, multicenter, open label study.

Phase I dose escalation and dose expansion, international, multicenter study of W0180 as single agent and in combination with pembrolizumab (anti-PD-1) in adult participants with locally advanced or metastatic solid tumors.